Eric Schmidt

Eric Schmidt is a seasoned biotechnology analyst currently at Cantor Fitzgerald since September 2023. Schmidt also serves as a board member and investment committee member for SOLVE FSHD since December 2022 and has held various board positions with companies such as REVOLUTION Medicines, Relmada Therapeutics, and Notch Therapeutics. Previously, Schmidt was the Chief Financial Officer at Allogene Therapeutics from June 2018 to August 2023 and worked as a research analyst at Cowen and Company for two decades. Academically, Schmidt holds a Doctor of Philosophy in Biochemistry and Molecular Biology from the Massachusetts Institute of Technology and a Bachelor of Arts in Chemistry from the University of Pennsylvania.